Business Wire - October 3, 2000
"This is a dramatic result, one that underscores, in the light of the other achievements we have recorded in this trial, that our gene medicine and technology designed to counter the HIV virus is on the right track," said Dean L. Engelhardt, Executive Vice President of Enzo. "It is also, we believe, a scientific milestone since to our knowledge no other technology has been successful in engrafting cells expressing a cloned gene in the bone marrow of adult subjects without first ablating the patient, a process in which blood cells are destroyed."
Enzo is currently compiling and analyzing data from the remaining five patients in the trial. The Company said that while the data is limited and must await further study, it is highly encouraged. "We believe that Enzo has taken an important step to reconstituting an individual's immune system with resistant cells, an exceptional achievement," said Dr. Engelhardt.
"These findings are very exciting. This novel approach may be one of the new treatment platforms we desperately need to confront the problem of resistance to the anti-viral cocktails," said Marcus A. Conant, MD, a leading physician in the management of HIV-1 infected patients and one of the principal investigators of the trial.
The Company said that it is focusing on preparations for a Phase II trial, and that pending submissions to the FDA, it had already begun negotiations with several hospitals at which the broader study would be conducted.
Enzo said that all the patients tolerated the procedure well. The new data that show that the progeny CD4+ cells are now in circulation indicate that it is possible to effectively reintroduce engineered cells into a patient, have them reestablish themselves and, importantly, reproduce progeny cells having the same engineered characteristics.
HGTV-43, the Company's proprietary gene medicine product, was developed to protect human immune cells against infection by a broad spectrum of strains of HIV-1 including its mutational variants. This medicine incorporates two proprietary technologies, plus additional techniques, all of which were successfully implemented during the trial. One involves insertion of a new type of genetic material into blood cells that has been shown to inhibit the growth of HIV-1. This technology, known as genetic antisense, utilizes a "mirror image" of a gene, called an antisense molecule, to block the virus.
The second technology is based on a novel vector designed to deliver the antisense molecule to the cell. This vector is employed to insert new genes into target cells with the objective of integrating the gene into the chromosome of the cell, in a process known as transduction. Enzo stated previously that it has achieved high levels of transduction within 18 hours, thus limiting inconvenience to the patient, and in achieving levels of stable gene transfer to target cells greater than 30%. The cells containing these new genes, when transferred to the patient, replicate and provide the patient with the newly inserted biological function. The Company believes that its proprietary vector system constitutes a technological breakthrough in the development of commercially viable gene medicine.
Effectively, Enzo has succeeded in developing and utilizing its proprietary vector for delivery of its HIV gene medicine into the patient's blood cells. With this vector, Enzo succeeded in achieving high levels of stable gene transfer within one day, as compared to previous procedures that required two or more weeks. These cells have been shown to persist in patients and to produce differentiated CD4+ immune cells. The engraftment of these blood cells expressing Enzo's anti-HIV-1 transgene brings the goal of reconstituting the immune system with virus resistant cells considerably closer to completion. Enzo Biochem is engaged in the research, development and manufacture of innovative health care products based on molecular biology and genetic engineering techniques, and in providing diagnostic services to the medical community.
Except for historical information, the matters discussed in this news release may be considered "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended Such statements include declarations regarding the intent, belief or current expectations of the Company and its management. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results.
Contact: Anreder Hirschhorn Silver and Company, New York Steven Anreder, 212/532-3232
001002
BW001003
Copyright © 2000 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .